<p>Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project</p>
Paola Bagella(Azienda Ospedaliero-Universitaria Careggi), Giordano Madeddu(University of Sassari), Chiara Dentone(Ospedale di Sanremo), Benedetto Maurizio Celesia(Ospedale Garibaldi), Giancarlo Orofino(Ospedale Amedeo di Savoia), Giuseppe Vittorio De Socio(University of Perugia), Nicola Squillace(Azienda Ospedaliera San Gerardo), Elena Ricci(Mario Negri Institute for Pharmacological Research), Barbara Menzaghi(Ospedale di Circolo di Busto Arsizio), Paolo Bonfanti(University of California San Diego), Lucia Taramasso(Ospedale Policlinico San Martino), Giovanni Francesco Pellicanò(University of Messina), Roberto Gulminetti(University of Pavia)
Cited by 28
Related Papers
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
|CHEST Journal|2021|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels
|medRxiv|2020|234
Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program
|Clinical Infectious Diseases|2012|208